XOLREMDI (mavorixafor)

Self-Administration-oral capsules

Diagnosis considered for coverage:

WHIM syndrome: Indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

Coverage Criteria:

For diagnosis of WHIM syndrome:

  • Diagnosis of WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome; AND

  • Patient has genotype confirmed variant of CXCR4 as detected by an FDA-approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA); AND

  • Patient has an absolute neutrophil count (ANC) less than or equal to 500 cells /µL; AND 

  • Patient is 12 years of age or older; AND

  • Prescribed by or in consultation with one of the following: 

    • Immunologist 

    • Hematologist 

    • Geneticist 

    • Allergist 

Reauthorization Criteria:

For diagnosis of WHIM syndrome:

  • Patient demonstrates positive clinical response to therapy (e.g., improvement in ANC, reduction in infections)

Coverage Duration:
  • Initial: 6 months

  • Reauthorization: 1 year

Dosing:

For diagnosis of WHIM syndrome:

  • Dosing is based on body weight:

    • Weight >50 kg: 400 mg once daily 

    • Weight ≤50 kg: 300 mg once daily

    • Dosage may be further adjusted based on multiple drug-drug interactions

  • Medication should be taken on an empty stomach after an overnight fast, and at least 30 minutes before food

  • Reduce daily dosage to 200 mg when used concomitantly with strong CYP3A4 inhibitors

Authorization is not covered for the following:
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • XOLREMDI, a selective CXCR4 antagonist, is the first therapy specifically indicated in patients with WHIM syndrome.

  • Use of XOLREMDI is contraindicated with drugs that are highly dependent on CYP2D6 for clearance.

  • Obtain an electrocardiogram when initiating, during concomitant use, and as clinically indicated in patients receiving concomitant medications with a known potential to prolong the QTc interval.

  • Per consult with immunologist/allergist, severe neutropenia (less than or equal to 500 cells per µL) is used in standard practice as a cut off for ANC levels.

 Policy Updates:
  • 12/01/2024 – New policy for Xolremdi approved by WHA P&T Committee. (P&T, 11/20/2024)

References:
  1. Xolremdi Prescribing Information. X4 Pharmaceuticals, Inc. Boston, MA. June 2024. 

  2. Per clinical consult with immunologist/ allergist, June 27, 2024. 

Last review date: December 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone